NCT04249778View on ClinicalTrials.gov

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

PHASE4CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

March 3, 2022

Study Completion Date

March 3, 2022

Conditions
Heart FailureDiabetes
Interventions
DRUG

Dapagliflozin

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.

DRUG

Placebo

Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.

Trial Locations (3)

19122

Temple University, Philadelphia

30322

Emory University Hospital, Atlanta

70118

Tulane University, New Orleans

All Listed Sponsors
lead

Emory University

OTHER

NCT04249778 - Dapagliflozin at Discharge on Hospital Heart Failure Readmission | Biotech Hunter | Biotech Hunter